Evaluation and outcomes of liver transplantation for hepatitis/hiv co-infection

Ishfaq Bhat, Sandeep Mukherjee

Research output: Chapter in Book/Report/Conference proceedingChapter


An estimated 180 million people worldwide are infected with hepatitis C virus (HCV). HCV is the most common blood borne infection in the United States with a prevalence nearly 4 fold greater than human immunodeficiency virus (HIV). It is the leading cause of end stage liver disease, hepatocellular carcinoma and liver transplantations in the United States. Hepatitis B virus (HBV)) and HCV are common among patients with HIV because of shared routes of viral transmission. Due to successful highly active antiretroviral therapy, opportunistic infections and related complications from Acquired Immune Deficiency Syndrome (AIDS) are less common causes of mortality in HIV patients. However, endstage liver disease due to chronic HBV and HCV infection is becoming a leading cause of death among persons with HIV infection worldwide with the risk of death due to liver disease is inversely related to the CD4 cell count.There has been a strong debate recently about the need for aggressive evaluation of co-infected patients with end stage liver disease for liver transplantation. This chapter will review the outcomes of liver transplantation for co-infected patients, important drug interactions and briefly discuss the ethical issues related to this vulnerable population/.

Original languageEnglish (US)
Title of host publicationHepatitis C and Liver Transplantation
PublisherNova Science Publishers, Inc.
Number of pages11
ISBN (Electronic)9781617611346
ISBN (Print)9781617286162
StatePublished - Jan 1 2010

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Evaluation and outcomes of liver transplantation for hepatitis/hiv co-infection'. Together they form a unique fingerprint.

Cite this